Is Wegovy as Effective as Ozempic for Weight Loss?

The misconception: same drug, same effect

A reasonable person reads that Wegovy and Ozempic both contain semaglutide and concludes they must do the same job at the same level. The label differences look like marketing. They're not.

The key is dose. Ozempic reaches a maximum of 1mg weekly in its original formulation, with a 2mg option added later, both studied in people with type 2 diabetes where the primary goal was blood-sugar control and secondary outcomes included modest weight reduction. Wegovy was developed from the ground up with weight management as the primary aim, using a much higher weekly dose that climbs to 2.4mg as standard maintenance, and now up to 7.2mg following approval by the MHRA in early 2026.

Dose matters enormously with GLP-1 medicines. The appetite-suppressing and gastric-emptying effects are dose-dependent, which is exactly why the STEP clinical programme tested Wegovy at doses Ozempic was never designed to reach. Calling them equivalent because they share an ingredient is a bit like saying two medicines with the same active compound but very different strengths must produce the same result. They don't. You can read more about how semaglutide works and why dose shapes the outcome.

Ozempic does cause some weight loss in people with diabetes (that is well-documented) but it was not studied for, and is not licensed for, weight management in the UK. Treating it as a weight-loss equivalent to Wegovy misreads both the evidence and the regulatory position.

What the Wegovy trial data actually showed

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. Over 68 weeks, participants taking semaglutide 2.4mg weekly alongside lifestyle changes lost an average of around 15% of their body weight, compared with about 2.4% on placebo. That is a meaningful clinical result, not a marginal one.

The newer 7.2mg dose narrows the gap with tirzepatide results still further; trials reported average weight loss of around 20.7% over 72 weeks at that dose, and the MHRA approved the dedicated single-dose 7.2mg Wegovy pen in April 2026 for adults with a BMI of 30 or above. The full picture of Wegovy's effectiveness covers both dose levels in more detail.

Ozempic was not part of the STEP programme. The weight outcomes seen in Ozempic's diabetes trials were secondary findings at lower doses in a different patient group. Quoting those figures as if they represent Ozempic's weight-loss potential, let alone as a comparison to Wegovy, overstates the evidence considerably. How effective semaglutide is depends almost entirely on which indication, which dose, and which patient population you are looking at.

Which semaglutide medicine is actually licensed for weight loss in the UK

The MHRA has been clear. Wegovy (semaglutide 2.4mg and above) holds a UK licence for weight management in adults with a BMI of 30 or higher, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Ozempic's UK licence covers type 2 diabetes. The regulatory difference between Wegovy and Ozempic is not a technicality, it shapes which medicine a prescriber can legitimately offer for weight management.

NICE recommended Wegovy for NHS use under technology appraisal TA875, published in March 2023, within specialist weight management services and subject to specific eligibility criteria. Ozempic does not feature in that recommendation because it is not the licensed weight-management product. Private prescriptions follow the same licenced-indication framework: a GPhC-registered prescriber assesses your clinical picture and prescribes the medicine that is both appropriate and authorised for your situation.

If you're looking at the cost of treatment, a breakdown of Wegovy pricing in the UK gives useful context on what a legitimate private prescription typically includes. That matters, because the licensed route is the safe one.

What is actually available for weight management, and how to access it

In the UK, two injectable medicines hold a licence for weight management in adults: Wegovy (semaglutide) and Mounjaro (tirzepatide). Mounjaro is a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed here, and the SURMOUNT-1 trial found average weight reductions of around 20 to 21% at the highest dose over 72 weeks. You can explore weight-loss treatment options to understand how the two compare and which might suit your circumstances.

Neither can be obtained legally without a prescription following a proper clinical assessment. Ozempic prescribed specifically for weight loss, without a diabetes diagnosis, sits outside its UK licence, any pharmacy offering it on that basis should prompt careful scrutiny. The 25mg oral Wegovy tablet, approved by the MHRA in June 2026 as the first oral GLP-1 licensed for weight management in the UK, is another option now available by private prescription, for those who prefer tablets to injections.

Our prescribers review every consultation the same day it arrives. No algorithm makes the decision. If you'd like to find out whether you're clinically suitable for Wegovy or Mounjaro, check your eligibility with a free consultation, there's no commitment and no charge to complete it.